Advanced Breast Cancer - algorithms from the 4th ESO-ESMO International Consensus Guidelines
Haven't had much time lately? Here's what you may have missed in the last few weeks.
Sign-up to receive the OncologyPRO alert
every 2 weeks.
Find all 2018 ESMO Guidelines
and
discover the ESMO Guidelines Slide Sets
!
Melanoma Adjuvant Setting - State of the Art , by Riccardo Marconcini
18 Jan 2019
Screening for hepatitis B and C viral infection at time of cancer diagnosis may be helpful
17 Jan 2019
Health-related quality of life results favour nivolumab plus ipilimumab over sunitinib for patients with treatment-naïve intermediate- and poor-risk...
16 Jan 2019
Women may experience an increased risk of breast cancer metastases for 10 years after giving birth
15 Jan 2019
Cancer patients who have at least one other medical condition are significantly less likely to be considered for and participate in a clinical trial...
14 Jan 2019
Survival may be inferior for rectal cancer patients who postpone surgery after achieving a complete clinical response to neoadjuvant therapy
There are two main goals to perform neoadjuvant systemic therapy for women with breast cancer. The first goal is to obtain a pathological complete response (PCA) and the second reason is because we want to perform a less aggressive surgery.In this OncologyPRO educational video of the "How to" series, Sofia Braga explains how to use neoadjuvant therapies in Breast cancer patients according to risk factors and tumour type.
13-16 Dec 2018, Geneva, Switzerland
02-03 Dec 2018, Milan, Italy
26-27 Nov 2018, Singapore
26-27 Nov 2018, Singapore
23-25 Nov 2018, Singapore, Singapore
23-24 Nov 2018, Zurich, Switzerland
21-22 Nov 2018, Singapore
20-22 Nov 2018, Singapore
20-21 Nov 2018, Singapore
16-17 Nov 2018, Lugano, Switzerland
09-10 Nov 2018, Lisbon, Portugal
08-11 Nov 2018, Amsterdam, Netherlands
02-03 Nov 2018, Zurich, Switzerland
19-23 Oct 2018, Munich, Germany
06-08 Oct 2018, Lugano, Switzerland
